Affiliation:
1. Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia); O.M. Filatov City Clinical Hospital No. 15
2. Federal State Budgetary Educational Institution of Further Professional Education "Russian Medical Academy of Continuous Professional Education" of the Ministry of Healthcare of the Russian Federation (FSBEI FPE RMACPE MOH Russia)
3. O.M. Filatov City Clinical Hospital No. 15
4. Ministry of Health of the Russian Federation
Abstract
The safety of COVID-19 pharmacotherapy is a relevant issue, first of all, because of the current lack of experience with using particular medicinal products and with off-label prescribing. The aim of the study was to analyse information on potential adverse drug reactions (ADRs) and their predictors in etiology- and pathogenesis-oriented COVID-19 therapy. According to literature data, the main clinically significant risk factors for COVID-19 patients to develop an ADR are the duration of their hospital stay, combined use of antivirals, polypharmacy, and their history of drug allergies. The most common adverse reactions to antivirals, to virus-neutralising antibodies, and to human anti-COVID-19 immunoglobulin and convalescent plasma are, respectively, gastrointestinal and hepatobiliary disor ders; gastrointestinal disorders, neurological disorders, and allergic reactions; and transfusion reactions (fever, chills, etc.). For pathogenesis-oriented therapy with systemic glucocorticosteroids, the most characteristic ADR is hyperglycaemia. Janus kinase inhibitors and interleukin inhibitors are most often associated with gastrointestinal disorders and hypertransaminasemia; neutropenia is also characteristic of a number of interleukin inhibitors. Haemo static adverse reactions to anticoagulants depend on the patient’s dosing regimen and condition. Drug-drug interactions are a common problem in COVID-19 treatment, with the combination of nirmatrelvir and ritonavir showing the largest number of significant interactions attributed to their pharmacokinetics. Currently, there is data on the role of pharmacogenetic biomarkers in the safety and clinical outcomes of COVID-19 therapy. Thus, to improve the safety of COVID-19 therapy, an integrated approach is needed that will take into account both the clinical, demographic, and pharmacogenetic predictors of ADRs and the risk of drug-drug interactions.
Reference58 articles.
1. Zyryanov SK, Zatolo-china KE, Kazakov AS. Current patient safety issues: the role of pharmacovigilance. Obshchestvennoe zdorovie = Public Health. 2022;2(3):25-34 (In Russ.) https://doi.org/10.21045/2782-1676-2021-2-3-25-34
2. Kostyleva MN, Belousov YuB, Gratsianskaya AN, Postnikov SS. Evaluation of safety of drug therapy in clinical practice. FARMAKOEKONOMIKA. Sovremen-naya farmakoekonomika i farmakoepidemiologiya = FARMAKOEKONOMIKA. Modern Pharmacoeconomics and Pharmacoepidemiology. 2014;7(1):27-32 (In Russ.)
3. Ivashchenko DV, Buromskaya NI, Savchenko LM, Shevchenko YS, Sychev DA. Global trigger tool value for revealing of unwanted events related to medical care in pediatrics. Meditsinskiy sovet = Medical Council. 2018;(17):56-66 (In Russ.) https://doi.org/10.21518/2079-701X-2018-17-56-65
4. Nazarenko GI, Kleymenova EB, Otdelenov VA, Payu-shik SA, Yashina LP, Sychev DA. The use of adverse event triggers to identify adverse drug reactions in a multidisciplinary hospital. Klinicheskaya far-makologiya i terapiya = Clinical Pharmacology and Therapy. 2015;24(4):55-62 (In Russ.)
5. Alshehail B, Al Jamea Z, Chacko R, Alotaibi F, Ismail N, Alshayban D. Incidence and risk factors of adverse drug reactions in patients with coronavirus disease 2019: a pharmacovigilance experience utilizing an ADR trigger tool. Saudi Pharm J. 2022;30(4):407-13. https://doi.org/10.1016/i.isps.2022.01.021